Episode 76: Leadership and Entrepreneurship with Samer Saab

Samer Saab

Episode 76: Leadership and Entrepreneurship with Samer Saab

Chadi shifts gears this week to sit down with a renowned business leader: Sameer Saab, founder and CEO of the experience management solution company Explorance. Sameer sheds light on the challenges of starting and running a successful business, especially during a once-in-a-century pandemic, and the services Explorance offers. The Great Resignation, surveys given to healthcare workers, burnout, immigrant struggles, transparency and flexibility with employees, balancing personal lives with business lives as the leader of a company, lessons in leadership, business values, and a whole host of other topics are covered in this wide-ranging and inspiring interview.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More